Use of Statins for Primary Prevention Among Individuals with CKD in the United States: A Cross-Sectional, Time-Trend Analysis

Chronic kidney disease (CKD) populations face an elevated risk of cardiovascular disease (CVD), yet many remain undertreated with statins for primary prevention of CVD despite meeting eligibility criteria. We examined trends in statin use for primary prevention among individuals with CKD before and after the release of the 2013 Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommending statin use for lipid management in selected adults with CKD. Cross-sectional time-trend analysis. The 2001-2020 National Health and Nutrition Examination Survey (NHANES) data permitted identification of individuals eligible for statin therapy per the 2013 KDIGO guidelines based on: (1) age ≥50 without self-reported CVD; (2) CKD, defined as estimated glomerular filtration rate